US · Healthcare · Drug Manufacturers - General
EPS came in at 1.35 against a street estimate of 1.21 — a beat of 11.6%.
Analysts rate Bristol-Myers Squibb Company a buy (10 buy, 16 hold, 1 sell out of 27) with an average price target of $65.25.
CONFIDENT Bristol Myers Squibb delivered strong growth, raised 2026 guidance and advanced several late-stage programs, though legacy-product erosion and key clinical readouts remain risks. Q3 FY26 U.S. growth benefited from Eliquis, Camzyos, Qvantig and Breyanzi; Europe faces Eliquis upcoming loss of exclusivity, while international Breyanzi demand remained strong. Analysts focused on Admiperant’s dose response and commercial potential, Zenbexus’s early launch, pipeline readouts and capital allocation. Management emphasized favorable safety, positive early uptake, disciplined development and continued investment. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.82% |
| Vanguard Capital Management, LLC | 6.52% |
| State Street Corp | 5.01% |
| JPMorgan Chase & Co | 3.51% |
| Charles Schwab Investment Management Inc | 3.31% |
| Geode Capital Management, LLC | 2.76% |
| Vanguard Portfolio Management, LLC | 2.29% |
| NORGES BANK | 1.80% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $13,069 million, up from $12,222 million in Q3 2025. Nine-month revenue was $37,532 million versus | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue increased 7% to $13.1 billion, or $13,069 million. • Growth Portfolio revenue rose 12% to $7.7 billion | 2026-10-29 |
| Quarterly report · Q2 2026 BRISTOL-MYERS SQUIBB COMPANY – FORM 10-Q SUMMARY Period Ended June 30, 2026 --- HEADLINE NUMBERS • Net product sales Q2 2026: $12,588 million vs. $ | 2026-07-30 |
| Results announced · Q3 2026 BRISTOL-MYERS SQUIBB Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $13.0 billion, up 6% (+5% excluding foreign exchange) versu | 2026-07-30 |
| Shareholder vote results · Q2 2026 BRISTOL-MYERS SQUIBB COMPANY – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 5, 2026 • Total votes cast across proposals: | 2026-05-08 |
| Quarterly report · Q1 2026 BRISTOL-MYERS SQUIBB COMPANY — Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues: $11,489 million (Q1 2026) vs. $11,201 million (Q1 2025) | 2026-04-30 |
| Results announced · Q2 2026 BRISTOL-MYERS SQUIBB Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Q1 2026 revenues: $11.5 billion, up 3% reported (+1% excluding forei | 2026-04-30 |
| Proxy statement · Q2 2026 BRISTOL-MYERS SQUIBB PROXY STATEMENT (DEF 14A) SUMMARY FOR RETAIL INVESTORS --- CEO COMPENSATION & CHANGE • Christopher S. Boerner (CEO) total comp | 2026-03-25 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.63 / share ex-date Oct 2, 2026 · pay Nov 2, 2026 | 2026-10-02 |
| Dividend | $0.63 / share ex-date Jul 2, 2026 · pay Aug 3, 2026 | 2026-07-02 |
| Dividend | $0.63 / share ex-date Apr 2, 2026 · pay May 1, 2026 | 2026-04-02 |
| Dividend | $0.63 / share ex-date Jan 2, 2026 · pay Feb 2, 2026 | 2026-01-02 |
| Dividend | $0.62 / share ex-date Oct 3, 2025 · pay Nov 3, 2025 | 2025-10-03 |
| Announcement | Date |
|---|---|
| Q1 2026 results reported; 2026 guidance reaffirmed, trending toward upper end Bristol Myers Squibb reported Q1 2026 results showing solid execution with revenues of $11.5 billion, up 3% year-over-year (1% excluding currency effects). The company's Growth Portfolio—new | 2026-04-30 |
| 2026 revenue and EPS guidance provided; dividend increased Bristol Myers Squibb reported 2025 results showing disciplined execution with mixed but encouraging trends. Total revenues were $48.2 billion (flat year-over-year), but the Growth Portfolio— | 2026-02-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bristol-Myers Squibb Company — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.